Nucleolin

Asia-Pacific Respiratory Syncytial Virus (RSV) Market to 2028 - Featuring AstraZeneca, Bavarian Nordic & Enanta Pharmaceuticals Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, March 27, 2020
Health, Infectious diseases, Mononegavirales, Viruses, Human orthopneumovirus, Paramyxoviridae, Orthopneumovirus, Medical specialties, Pneumoviridae, Microbiology, RSV, Lower respiratory tract infection, Nucleolin, Human metapneumovirus

Human Respiratory Syncytial Virus (RSV) is an enveloped, single-stranded, negative-sense RNA orthopneumovirus belonging to the family of Pneumoviridae.

Key Points: 
  • Human Respiratory Syncytial Virus (RSV) is an enveloped, single-stranded, negative-sense RNA orthopneumovirus belonging to the family of Pneumoviridae.
  • Respiratory Syncytial Virus (RSV) is the leading cause of lower respiratory tract infections (LRTIs) in infants, with a peak age of hospitalization between 2-3 months of age.
  • Respiratory Syncytial Virus (RSV) is also an important cause of hospitalizations and deaths in elderly adults.
  • It is likely that several first-in-class products for the management of Respiratory Syncytial Virus (RSV) will coexist simultaneously by 2028, including both vaccines and antivirals for treatment of severe or breakthrough Respiratory Syncytial Virus (RSV) infections.

Curadigm announces the selection of its Nanoprimer technology by the National Cancer Institute for a characterization & development collaboration

Retrieved on: 
Monday, March 9, 2020
Research, FDA, Clinical trials, Biotechnology, Other Health, Health, Pharmaceutical, Science, Oncology, Nucleolin, Proteins, Nanomedicine

The broad utility of the Nanoprimer technology is due to its unique nanomedicine approach to improve therapeutic action without modifying the therapeutic in any way.

Key Points: 
  • The broad utility of the Nanoprimer technology is due to its unique nanomedicine approach to improve therapeutic action without modifying the therapeutic in any way.
  • Rather, the Nanoprimer is administered intravenously just prior to a therapeutic, specifically and transiently occupying the liver pathways responsible for clearance.
  • Through this collaboration, the NCL, a leader in the characterization and development of Nanomedicines, will perform in-depth pre-clinical characterizations.
  • The selection of our nanoprimer by the NCL is a major step for Curadigm, said Matthieu Germain, CEO of Curadigm.

Respiratory Syncytial Virus (RSV): Forecast in Asia-Pacific Markets to 2028

Retrieved on: 
Tuesday, December 31, 2019
Medical specialties, Human orthopneumovirus, Paramyxoviridae, RSV, Medicine, Lower respiratory tract infection, Branches of biology, Nucleolin, Mononegavirales, Orthopneumovirus, Palivizumab

DUBLIN, Dec. 31, 2019 /PRNewswire/ -- The "Respiratory Syncytial Virus (RSV): Forecast in Asia-Pacific Markets to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Dec. 31, 2019 /PRNewswire/ -- The "Respiratory Syncytial Virus (RSV): Forecast in Asia-Pacific Markets to 2028" report has been added to ResearchAndMarkets.com's offering.
  • Respiratory Syncytial Virus (RSV) is the leading cause of lower respiratory tract infections (LRTIs) in infants, with a peak age of hospitalization between 2-3 months of age.
  • The main driver of growth will be the launch of new products to prevent medically-significant Respiratory Syncytial Virus (RSV) infections, including the first products to be licensed for Respiratory Syncytial Virus (RSV) in India and urban China.
  • It is likely that several first-in-class products for the management of Respiratory Syncytial Virus (RSV) will coexist simultaneously by 2028, including both vaccines and antivirals for treatment of severe or breakthrough Respiratory Syncytial Virus (RSV) infections.

Respiratory Syncytial Virus (RSV): Forecast in Asia-Pacific Markets to 2028

Retrieved on: 
Tuesday, December 24, 2019
Human orthopneumovirus, Paramyxoviridae, RSV, Nucleolin, Mononegavirales, Orthopneumovirus

Respiratory Syncytial Virus (RSV) is also an important cause of hospitalizations and deaths in elderly adults.

Key Points: 
  • Respiratory Syncytial Virus (RSV) is also an important cause of hospitalizations and deaths in elderly adults.
  • The main driver of growth will be the launch of new products to prevent medically-significant Respiratory Syncytial Virus (RSV) infections, including the first products to be licensed for Respiratory Syncytial Virus (RSV) in India and urban China.
  • It is likely that several first-in-class products for the management of Respiratory Syncytial Virus (RSV) will coexist simultaneously by 2028, including both vaccines and antivirals for treatment of severe or breakthrough Respiratory Syncytial Virus (RSV) infections.
  • The latest research report "Respiratory Syncytial Virus (RSV): Forecast in Asia-Pacific Markets to 2028" helps in answering the following question with regards to Respiratory Syncytial Virus (RSV) and its therapeutic market in Asia Pacific.

Actress Vanessa Lachey Joins Forces with Sobi to Raise Awareness of Severe RSV Disease and Steps Parents Can Take to Prevent It

Retrieved on: 
Tuesday, October 1, 2019
Infectious diseases, Baby, Maternity, Biotechnology, Other Health, Pharmaceutical, Consumer, Health, Human orthopneumovirus, Paramyxoviridae, RSV, Nucleolin, AstraZeneca, Mononegavirales, Palivizumab

View the full release here: https://www.businesswire.com/news/home/20191001005447/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20191001005447/en/
    Actress Vanessa Lachey Joins Forces with Sobi to Raise Awareness of Severe RSV Disease and Steps Parents Can Take to Prevent It (Photo: Business Wire)
    When my son Phoenix was born prematurely, no one ever informed me that this could make him more vulnerable to RSV.
  • Phoenix is doing great now, but his hospitalization due to RSV was one of the scariest experiences in my life.
  • Our product portfolio includes multiple approved treatments, focused on immunology and genetics/metabolism.
  • Systematic literature review assessing tobacco smoke exposure as a risk factor for serious respiratory syncytial virus disease among infants and young children.

World Respiratory Syncytial Virus Diagnostic Market Report 2019: Opportunities and Forecasts, 2017-2023 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 6, 2019
Health, Infectious diseases, Medical specialties, Respiratory diseases, Medicine, Infectious diseases, Human orthopneumovirus, Paramyxoviridae, Bronchiolitis, RSV, Nucleolin, Pneumonia, Respiratory tract infection, Human coronavirus NL63

The "World Respiratory Syncytial Virus (RSV) Diagnostic Market - Opportunities and Forecasts, 2017 - 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "World Respiratory Syncytial Virus (RSV) Diagnostic Market - Opportunities and Forecasts, 2017 - 2023" report has been added to ResearchAndMarkets.com's offering.
  • Respiratory syncytial virus (RSV) is a virus which causes respiratory infections such as bronchiolitis and pneumonia.
  • As the clinical symptoms of RSV infections are indistinguishable from other respiratory infections, there is a growing need for rapid, specific and sensitive diagnostic techniques.
  • The RSV Diagnostic Market by End Users:
    The major consumers for diagnostic kits include Hospitals, Nursing homes, Commercial Laboratories, and Public Health Laboratories.

Aridis Pharmaceuticals Enters Into Equity Purchase and Option Agreements with The Serum Institute of India, Ltd for Exclusive License to Products and MabIgX® Platform Technology

Retrieved on: 
Tuesday, July 30, 2019
Medical specialties, Biology, Biotechnology, Medicine, Immunology, RSV, Monoclonal antibody, Human orthopneumovirus, Nucleolin, Royalty payment, MAbs

The agreement grants SIBV the option to license multiple programs from Aridis and access the Company's MabIgX platform technology for asset identification and selection.

Key Points: 
  • The agreement grants SIBV the option to license multiple programs from Aridis and access the Company's MabIgX platform technology for asset identification and selection.
  • Furthermore, under the license agreement, Aridis will receive future milestone payments for achieving product development and commercial objectives, along with royalties on net sales.
  • The option includes the right to acquire an exclusive, worldwide license (excluding China) to AR-201, a preclinical fully human mAb for the prevention of respiratory syncytial virus (RSV).
  • MabIgX is Aridis' proprietary technology platform to rapidly identify rare, potent antibody-producing B-cells from patients who have successfully overcome an infection to produce mAbs.

ReViral Announces Grant of Key US Composition of Matter Patent for Their Respiratory Syncytial Virus Inhibitor Programme

Retrieved on: 
Monday, April 8, 2019
Health, Biotechnology, Pharmaceutical, General Health, Human orthopneumovirus, Paramyxoviridae, RSV, Nucleolin, Antiviral drug, Viruses, Branches of biology, Mononegavirales, Biology, Orthopneumovirus, Larry J. Anderson, Health, Biotechnology, Pharmaceutical, General Health

ReViral Ltd., a clinical-stage company focused on developing novel, anti-viral compounds that target respiratory syncytial virus (RSV), today announced that the the United States Patent and Trademark Office (USPTO) recently granted patent US10,106,539 entitled Spiro-Indolines for the Treatment and Prophylaxis of Respiratory Syncytial Virus Infection (RSV).

Key Points: 
  • ReViral Ltd., a clinical-stage company focused on developing novel, anti-viral compounds that target respiratory syncytial virus (RSV), today announced that the the United States Patent and Trademark Office (USPTO) recently granted patent US10,106,539 entitled Spiro-Indolines for the Treatment and Prophylaxis of Respiratory Syncytial Virus Infection (RSV).
  • This composition of matter patent claims certain inhibitors of the fusion protein of the respiratory syncytial virus (RSV), including RV521, the Companys lead pipeline asset.
  • ReViral is progressing its lead drug candidate (RV521), a highly potent and orally bioavailable potential treatment for RSV infections.
  • ReViral is a clinical-stage company focused on developing novel, anti-viral compounds that target respiratory syncytial virus (RSV).